CINCINNATI — Prasco Laboratories has entering a marketing and distribution agreement with Eli Lilly and Co. to market an authorized generic version of Zyprexa tablets and Zyprexa Zydis orally disintegrating tablets in the United States.

Prasco said Thursday that it will market six strengths of olanzapine tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg) and four strengths of olanzapine orally disintegrating tablets (5 mg, 10 mg, 15 mg and 20 mg).

Financial terms of the deal weren’t disclosed. Plans call for Prasco to start distribution of both products upon the first abbreviated new drug application (ANDA) entrant into the market.

"We are especially excited to welcome Eli Lilly and Co. to our Prasco family of partners," Prasco chief executive officer E. Thomas Arington said in a statement. "Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the olanzapine launch through our new Lilly relationship," he added.

An antipsychotic medication, olanzapine is used to treat the symptoms of such conditions as schizophrenia and bipolar disorder.